Payment overview · 2025
General Payments
$197.61
8 reported records · 6 companies
Healthcare provider profile · identity verified
Constance Strbich, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · ENGLEWOOD, FL · NPI 1033148978
Verified facts
What the public records show
CMS Open Payments records show Constance Strbich, D.O. received $197.61 in general payments during 2025 across 8 reported records.
Astellas Pharma US Inc accounted for 55.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $109.88 | 55.6% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.19 | 11.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.07 | 9.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.58 | 8.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.10 | 8.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.79 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.61 | 7 |
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $49.88 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 107 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
107 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 489 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 128 |
| Losartan Potassium | Losartan Potassium | 348 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 261 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 68 |
| Lisinopril | Lisinopril | 191 | 64 |
| Alprazolam | Alprazolam | 190 | 50 |
| Omeprazole | Omeprazole | 180 | 62 |
| Simvastatin | Simvastatin | 150 | 39 |
| Trazodone Hcl | Trazodone Hcl | 143 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 39 |
| Sertraline Hcl | Sertraline Hcl | 111 | 31 |
| Gabapentin | Gabapentin | 109 | 35 |
| Ezetimibe | Ezetimibe | 108 | 42 |
| Mounjaro | Tirzepatide | 107 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 45 |
| Ozempic | Semaglutide | 99 | 17 |
| Metformin Hcl | Metformin Hcl | 96 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 28 |
| Tramadol Hcl | Tramadol Hcl | 91 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 24 |
| Montelukast Sodium | Montelukast Sodium | 83 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 23 |
| Lorazepam | Lorazepam | 82 | 22 |
| Methylprednisolone | Methylprednisolone | 77 | 64 |
| Azithromycin | Azithromycin | 72 | 57 |
| Bupropion Xl | Bupropion Hcl | 72 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 30 |
| Furosemide | Furosemide | 71 | 31 |
| Cephalexin | Cephalexin | 66 | 46 |
| Metformin Hcl Er | Metformin Hcl | 66 | 24 |
| Alendronate Sodium | Alendronate Sodium | 65 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 21 |
| Meloxicam | Meloxicam | 60 | 22 |
| Mirtazapine | Mirtazapine | 59 | 24 |
| Potassium Chloride | Potassium Chloride | 58 | 23 |
| Jardiance | Empagliflozin | 56 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 16 |
| Eliquis | Apixaban | 51 | 17 |
| Fenofibrate | Fenofibrate | 51 | 15 |
| Allopurinol | Allopurinol | 49 | 16 |
| Famotidine | Famotidine | 49 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 15 |
| Celecoxib | Celecoxib | 38 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 25 |
| Ondansetron Odt | Ondansetron | 35 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 35 | 13 |
| Estradiol | Estradiol | 34 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 12 |
| Atenolol | Atenolol | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 27 |
| Prednisone | Prednisone | 30 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 11 |
| Valacyclovir | Valacyclovir Hcl | 30 | 17 |
| Ketoconazole | Ketoconazole | 29 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | 11 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 22 |
| Topiramate | Topiramate | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Carvedilol | Carvedilol | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Nystatin | Nystatin | 21 | 11 |
| Cefdinir | Cefdinir | 20 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $197.61 · 8 records | Astellas Pharma US Inc | BREZTRI, CONTRAVE, MOUNJARO, NUZYRA, TRELEGY ELLIPTA, Veozah, XHANCE, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error